AVBP

Arrivent Biopharma Inc

Add to Watchlist

Advanced Chart

17.390

-0.6(-3.335%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.230

Open

18.230

VWAP

17.32

Vol

523.52K

Mkt Cap

645.18M

Low

16.900

Amount

9.07M

EV/EBITDA(TTM)

Total Shares

37.10M

491.36M

EV/OCF(TTM)

P/S(TTM)

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.

9 Analyst Rating

130.76% Upside

Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 40.13 USD with a low forecast of 32.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

130.76% Upside

Current: 17.390

Low

32.00

Averages

40.13

High

45.00

130.76% Upside

Current: 17.390

Low

32.00

Averages

40.13

High

45.00

Goldman Sachs

Corinne Johnson

initiated

$33

2025-07-10

Reason

Goldman Sachs

Corinne Johnson

Price Target

$33

2025-07-10

initiated

Reason

Goldman Sachs analyst Corinne Johnson resumed coverage of ArriVent Biopharma with a Buy rating and $33 price target. The firm sees a high probability that the Phase3 FURVENT results demonstrate competitive clinical efficacy.

Oppenheimer

Outperform

maintain

$39 -> $44

2025-06-24

Reason

Oppenheimer

Price Target

$39 -> $44

2025-06-24

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on ArriVent Biopharma to $44 from $39 and keeps an Outperform rating on the shares. ArriVent announced a positive update from firmonertinib's Phase 1b PACC study with 10M longer follow-up, with results meeting the firm's prior best-case scenario, with the 240mg Firmo dose improving confirmed overall response rate to 68.2%, and showing a mean progression free survival of 16M and median duration of response of 14.6M, with a manageable safety profile, the analyst tells investors in a research note.

Clear Street

Kaveri Pohlman

Buy

initiated

$32

2025-06-24

Reason

Clear Street

Kaveri Pohlman

Price Target

$32

2025-06-24

initiated

Buy

Reason

Clear Street analyst Kaveri Pohlman initiated coverage of ArriVent Biopharma with a Buy rating and $32 price target. Firmonertinib, ArriVent's sole clinical asset, demonstrates "compelling validation" through four years of commercial success in China for classical epidermal growth factor receptor non-small cell lung cancer mutations, delivering efficacy comparable to osimertinib and lazertinib while exhibiting potentially best-in-class activity in atypical EGFR mutations, the analyst tells investors in a research note. The firm believes the company's focus on "underserved" PACC mutations and EGFR exon20ins markets positions it favorably against limited competition.

Citi

Buy

maintain

$36 -> $40

2025-06-23

Reason

Citi

Price Target

$36 -> $40

2025-06-23

maintain

Buy

Reason

Citi raised the firm's price target on ArriVent Biopharma to $40 from $36 and keeps a Buy rating on the shares, arguing that the follow up proof-of-concept data from the Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer harboring EGFR PACC mutations "support an increasingly bullish view of the opportunity in this segment of the NSCLC market." Momentum appears to be building and the stock should trade well into the second half, says the analyst, whose raised target reflects a higher 60% view of the odds of success in the PACC segment, up from about 50% previously.

Citi

Buy

maintain

$36 -> $40

2025-06-23

Reason

Citi

Price Target

$36 -> $40

2025-06-23

maintain

Buy

Reason

JonesResearch

NULL -> Buy

initiated

$40

2025-05-20

Reason

JonesResearch

Price Target

$40

2025-05-20

initiated

NULL -> Buy

Reason

JonesResearch initiated coverage of ArriVent Biopharma with a Buy rating and $40 price target. ArriVent is the leading oral EGFR TKI in front-line atypical EGFR mutated non-small cell lung cancer - a monotherapy regimen against EGFR exon 20 insertion and PACC mutations, the analyst tells investors in a research note. The firm expects pivotal Phase 3 data from EGFR ex20ins mutated lung cancer in the second half of 2025, and potential FDA approval within 12-15 months.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arrivent Biopharma Inc (AVBP.O) is -6.07, compared to its 5-year average forward P/E of -7.27. For a more detailed relative valuation and DCF analysis to assess Arrivent Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.27

Current PE

-6.07

Overvalued PE

-6.25

Undervalued PE

-8.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.26

Current EV/EBITDA

-4.77

Overvalued EV/EBITDA

-3.88

Undervalued EV/EBITDA

-6.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00